Immunochemotherapy with intensive consolidation for primary CNS lymphoma: A pilot study and prognostic assessment by diffusion-weighted MRI

Clinical Cancer Research

Volumn 18, Issue 4, 2012, Pages 1146-1155

  Wieduwilt, Matthew J ^a,f   Valles, Francisco ^a   Issa, Samar ^d   Behler, Caroline M ^a,b   Hwang, James ^b   McDermott, Michael ^b,c   Treseler, Patrick ^a,b   O'Brien, Joan ^e   Shuman, Marc A ^a,b   Cha, Soonmee ^a,b   Damon, Lloyd E ^a,b   Rubenstein, James L ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d MIDDLEMORE HOSPITAL   (New Zealand)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYTARABINE; DAPSONE; DIPHENHYDRAMINE; DOXORUBICIN; ETOPOSIDE; FLUCONAZOLE; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; LEVOFLOXACIN; METHOTREXATE; MOXIFLOXACIN; PARACETAMOL; PREDNISONE; RITUXIMAB; TEMOZOLOMIDE; VINCRISTINE; VORICONAZOLE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN RADIATION; BRAIN TOXICITY; CANCER IMMUNOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONFUSION; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; IMAGE ANALYSIS; INFECTION PREVENTION; KERATOCONJUNCTIVITIS; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PILOT STUDY; PNEUMOCYSTIS PNEUMONIA; PREDICTIVE VALUE; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CONSOLIDATION CHEMOTHERAPY; CYTARABINE; DACARBAZINE; DIFFUSION MAGNETIC RESONANCE IMAGING; ETOPOSIDE; FEMALE; HUMANS; IMMUNOTHERAPY; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; PROGNOSIS; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84857098166     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0625     Document Type: Article

References (43)

1. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998;16:859-63. (Pubitemid 28108717)
2. Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol 2007;25:4730-5. (Pubitemid 350086474)
3. Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol 1998;16:864-71. (Pubitemid 28108718)
4. Fliessbach K, Helmstaedter C, Urbach H, Althaus A, Pels H, Linnebank M, et al. Neuropsychological outcome after chemotherapy for primary CNS lymphoma: a prospective study. Neurology 2005;l64:1184-8.
5. Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, et al. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol 2003;21:1044-9. (Pubitemid 46594133)
6. Herrlinger U, Schabet M, Brugger W, Kortmann RD, Kuker W, Deckert M, et al. German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma. Ann Neurol 2002;51:247-52. (Pubitemid 34111448)
7. Ott RJ, Brada M, Flower MA, Babich JW, Cherry SR, Deehan BJ. Measurements of blood-brain barrier permeability in patients undergoing radiotherapy and chemotherapy for primary cerebral lymphoma. Eur J Cancer 1991;27:1356-61.
8. Osoba D, Brada M, Yung WK, Prados MD. Health-related quality of life in patients with anaplastic astrocytoma during treatment with temozolomide. Eur J Cancer 2000;36:1788-95. (Pubitemid 30639499)
9. Osoba D, Brada M, Yung WK, Prados M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J Clin Oncol 2000;18:1481-91. (Pubitemid 30205394)
10. Reni M, Ferreri AJ, Landoni C, Villa E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J Natl Cancer Inst 2000;92:575-6. (Pubitemid 30212321)
11. Reni M, Zaja F, Mason W, Perry J, Mazza E, Spina M, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007;96:864-7. (Pubitemid 46452291)
12. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004;101:139-45. (Pubitemid 38812433)
13. Damon LE, Johnson JL, Niedzwiecki D, Cheson BD, Hurd DD, Bartlett NL, et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J Clin Oncol 2009;27:6101-8.
14. Damon L, Damon LE, Gaensler K, Kaplan L, Martin T 3rd, Rubenstein J, et al. Impact of intensive PBSC mobilization therapy on outcomes following auto-SCT for non-Hodgkin's lymphoma. Bone Marrow Transplant 2008;42:649-57.
15. Linker CA, Owzar K, Powell B, Hurd D, Damon LE, Archer LE, et al. Auto-SCT for AML in second remission: CALGB study 9620. Bone Marrow Transplant 2009;44:353-9.
16. Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001;19:742-9. (Pubitemid 32119089)
17. Wilson WH, Bryant G, Bates S, Fojo A, Wittes RE, Steinberg SM, et al. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1573-82. (Pubitemid 23228265)
18. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717-24.
19. Relling MV, Mahmoud HH, Pui CH, Sandlund JT, Rivera GK, Ribeiro RC, et al. Etoposide achieves potentially cytotoxic concentrations in CSF of children with acute lymphoblastic leukemia. J Clin Oncol 1996;14:399-404. (Pubitemid 26051000)
20. Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007;18:149-57. (Pubitemid 46152515)
21. Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009;374:1512-20.
22. Lee EJ, Lee SK, Agid R, Bae JM, Keller A, Terbrugge K. Preoperative grading of presumptive low-grade astrocytomas on MR imaging: diagnostic value of minimum apparent diffusion coefficient. AJNR Am J Neuroradiol 2008;29:1872-7.
23. Yamasaki F, Kurisu K, Satoh K, Arita K, Sugiyama K, Ohtaki M, et al. Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 2005;235:985-91. (Pubitemid 40695898)
24. Ellingson BM, Malkin MG, Rand SD, Connelly JM, Quinsey C, LaViolette PS, et al. Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010;31:538-48
25. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, et al. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst 2000;92:2029-36. (Pubitemid 32045900)
26. Kitis O, Altay H, Calli C, Yunten N, Akalin T, Yurtseven T. Minimum apparent diffusion coefficients in the evaluation of brain tumors. Eur J Radiol 2005;55:393-400. (Pubitemid 41215567)
27. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002;224:177-83. (Pubitemid 34680392)
28. Politi LS, Forghani R, Godi C, Resti AG, Ponzoni M, Bianchi S, et al. Ocular adnexal lymphoma: diffusion-weighted mr imaging for differential diagnosis and therapeutic monitoring. Radiology 2010;256:565-74.
29. Ross BD, Moffat BA, Lawrence TS, Mukherji SK, Gebarski SS, Quint DJ, et al. Evaluation of cancer therapy using diffusion magnetic resonance imaging. Mol Cancer Ther 2003;2:581-7.
30. Moffat BA, Chenevert TL, Meyer CR, McKeever PE, Hall DE, Hoff BA, et al. The functional diffusion map: an imaging biomarker for the early prediction of cancer treatment outcome. Neoplasia 2006;8:259-67.
31. Lee KC, Moffat BA, Schott AF, Layman R, Ellingworth S, Juliar R, et al. Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy. Clin Cancer Res 2007;13:443-50. (Pubitemid 46225348)
32. Barajas RF Jr., Rubenstein JL, Chang JS, Hwang J, Cha S. Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma. AJNR Am J Neuroradiol 2010;31:60-6.
33. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005;23:5034-43. (Pubitemid 46224010)
34. Cher L, Glass J, Harsh GR, Hochberg FH. Therapy of primary CNS lymphoma with methotrexate-based chemotherapy and deferred radiotherapy: preliminary results. Neurology 1996;46:1757-9. (Pubitemid 26185811)
35. Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003;21:266-72. (Pubitemid 46606155)
36. Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006;24:5711-5. (Pubitemid 46631313)
37. Sandor V, Stark-Vancs V, Pearson D, Nussenblat R, Whitcup SM, Brouwers P, et al. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. J Clin Oncol 1998;16:3000-6. (Pubitemid 28417419)
38. Pels H, Schmidt-Wolf IG, Glasmacher A, Schulz H, Engert A, Diehl V, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol 2003;21:4489-95. (Pubitemid 46594018)
39. Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol 2010;11:1036-47.
40. Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003;21:4151-6. (Pubitemid 46606183)
41. Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. Differential gene expression in central nervous system lymphoma. Blood 2009;113:266-7; author reply 267-8.
42. Bazzoli E, Iwamoto FM, Zelenetz AD, Deangelis LM, Abrey LE. Synchronous presentation of systemic and brain non-Hodgkin lymphoma. Leuk Lymphoma 2008;49:2370-3.
43. Rubenstein JL, Johnson J, Jung SH, Cheson BD, Kaplan LD. Intensive chemotherapy and immunotherapy, without brain irradiation, in newly diagnosed patients with primary CNS lymphoma: results of CALGB 50202. Blood 2010;116:763.